Financial Data and Key Metrics Changes - Cardinal Health reported a record financial performance for fiscal year 2023, achieving a non-GAAP EPS of $5.79, reflecting a 14% growth year-over-year [6][10] - The company generated $205 billion in revenue for fiscal 2023, a 13% increase compared to the previous year, with gross margin rising 5% to $6.9 billion [15][16] - Adjusted free cash flow reached $2.8 billion, with a strong cash position of $4 billion at year-end [17][18] Business Line Data and Key Metrics Changes - In the Pharma segment, revenue increased by 15% to $49.7 billion in Q4, with segment profit rising 12% to $504 million, driven by strong performance in generics and specialty products [10][11] - The Medical segment reported flat revenue of $3.8 billion in Q4 but achieved a profit of $82 million, a significant improvement from a loss in the prior year [12][13] - For the full year, Pharma segment profit increased 13% to $2 billion, while Medical segment profit decreased 49% to $111 million due to lower volumes and unfavorable sales mix [16] Market Data and Key Metrics Changes - The company noted broad-based strength in pharmaceutical demand across various product categories, including brand, specialty, consumer health, and generics [10][11] - The Medical segment experienced a decrease in products and distribution sales, partially offset by growth in at-home solutions [12] Company Strategy and Development Direction - Cardinal Health is focused on three strategic imperatives: enhancing the Pharma segment's resilience, executing the Medical Improvement Plan, and maximizing shareholder value [7][9] - The company is investing in its Nuclear & Precision Health Solutions business and has launched the Navista Network to support community oncologists [8][27] - Cardinal Health aims to achieve a 12% to 14% EPS growth CAGR from fiscal 2024 to 2026, building on a higher fiscal 2023 baseline [22][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate inflation and supply chain challenges, with expectations of improved profitability in fiscal 2024 [31][36] - The company anticipates continued growth in the Pharma segment, particularly from GLP-1 medications, while the Medical segment is expected to improve sequentially throughout the year [19][21] Other Important Information - Cardinal Health completed a merger with BlackRock's Transaction Data Systems, which is expected to accelerate future growth [9] - The company returned over $2.5 billion to shareholders, including a $500 million accelerated share repurchase program [18] Q&A Session Summary Question: Clarification on GLP-1 impact on revenue guidance - Management confirmed that the revenue guidance increase is primarily due to GLP-1 medications, which are lower margin but contribute to overall revenue growth [40] Question: Core performance metrics for Medical segment - Management clarified that the core performance for the Medical segment was approximately $60 million, with additional contributions from seasonality and one-time items [42][43] Question: Progress on Navista offering - Management highlighted that the Navista Network is being built on existing capabilities and is focused on supporting community oncologists, with new leadership and customer engagement initiatives in place [51][52] Question: Capital allocation priorities for fiscal 2024 - Management indicated a disciplined approach to capital allocation, focusing on organic growth investments, litigation payments, and shareholder returns [76]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Cardinal Health, Inc. (NYSE:CAH) Q3 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Kevin Moran - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Michael Cherny - Bank of America Lisa Gill - JPMorgan Kevin Caliendo - UBS Elizabeth Anderson - Evercore ISI Eric Percher - Nephron George Hill - Deutsche Bank Eric Coldwell - Baird Steven Valiquette - Barclays Daniel Grosslight - Citi Charles Rhyee ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

Financial Data and Key Metrics Changes - Total company revenue increased by 13% and gross margin increased by 3%, driven primarily by the Pharmaceutical segment [11] - Operating earnings were $467 million, consistent with the previous year, reflecting growth in the Pharma segment profit offset by a decline in Medical segment profit [11] - Earnings per share (EPS) grew by 4% to $1.32, with a diluted weighted average share count of 263 million, down 6% year-over-year due to share repurchases [12] Business Line Data and Key Metrics Changes - **Pharmaceutical Segment**: Revenue increased by 15% to $48 billion, with segment profit rising by 9% to $464 million, driven by growth in branded and specialty pharmaceutical sales [13][14] - **Medical Segment**: Revenue decreased by 7% to $3.8 billion, with segment profit declining by 66% to $17 million, primarily due to lower product and distribution sales [16] Market Data and Key Metrics Changes - Strong overall pharmaceutical demand was noted, particularly from large customers, with contributions from new customers and seasonal products [14] - The Medical segment experienced volume softness, but there was a slight improvement in PPE volumes sequentially [17] Company Strategy and Development Direction - The company is focused on three strategic priorities: executing the medical improvement plan, enhancing the growth of the Pharmaceutical segment, and maximizing shareholder value [10][22] - Investments are being made in expanding the Cardinal Health brand portfolio and optimizing supply chain operations to mitigate inflation impacts [24][25] - The company plans to hold an Investor Day on June 8th to discuss long-term financial outlook and growth strategies [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the Pharmaceutical segment and anticipated gradual improvement in the Medical segment [21] - The company raised its EPS guidance for fiscal 2023, reflecting improved outlooks for the Pharmaceutical segment and interest income [18] - Management acknowledged ongoing inflationary pressures but noted effective mitigation actions, expecting to exit the year with at least 50% inflation mitigation [20][23] Other Important Information - The company completed a $1 billion accelerated share repurchase program and initiated a new $250 million program, with expectations of $1.5 billion to $2 billion in share repurchases for fiscal 2023 [12] - The company reported a cash position of $3.7 billion with no outstanding borrowings on its credit facility [13] Q&A Session All Questions and Answers Question: Expectations around surgical procedures and staffing issues - Management acknowledged constraints impacting growth in the Medical segment and anticipated gradual improvement in volumes as staffing issues resolve [32][33] Question: Pharma improvement and interest expense guidance - Management indicated that the improvement in the Pharma segment is primarily driven by volume, with interest expense guidance reflecting changes in cash balances rather than significant differences in interest rates [40][41][42] Question: Concerns or headwinds built into EPS guidance - Management provided a balanced outlook, noting that while the Pharma segment is expected to grow, the Medical segment has areas of concern that need to be monitored [45][47][56] Question: Opportunities in COVID treatments and core Pharma segment - Management noted limited participation in COVID treatments but indicated potential opportunities for 2024 and beyond as commercialization opens up [50][52] Question: Pricing and customer receptivity in Med/Surg - Management discussed a consistent approach to pricing adjustments and the desire to work collaboratively with customers to address challenges [61][62] Question: Size and growth of the at-home solutions business - Management confirmed that the at-home solutions business generated $2.4 billion in revenue last year, with approximately 9% growth in the first two quarters [68]

Q2 FY23 Cardinal Health, Inc. Earnings Call Forward-looking statements and GAAP reconciliation Cautions Concerning Forward-Looking Statements This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," “will," "should," "could," "would," "project," "continue,” "likely," and similar expressions ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other ju ...

Cardinal Health, Inc. (NYSE:CAH) 41st Annual J.P. Morgan Healthcare Conference January 9, 2023 1:30 PM ET Company Participants Jason Hollar - Chief Executive Officer Conference Call Participants Lisa Gill - JPMorgan Lisa Gill Good morning. My name is Lisa Gill and I'm the healthcare services analyst with J.P. Morgan. It is with great pleasure this morning that we have with us Cardinal Health. Presenting for Cardinal Health is CEO, Jason Hollar. Post Jason's presentation, he and I will sit down for a quick f ...

Cardinal Health Inc. 41st Annual JP Morgan Conference January 9, 2023 Jason Hollar Chief Executive Officer ...

Summary of Cardinal Health, Inc. Conference Call Company Overview - **Company**: Cardinal Health, Inc. (NYSE: CAH) - **Event**: Evercore ISI 5th Annual Healthcare Conference - **Date**: November 30, 2022 Key Industry Insights - **Medical Improvement Plan**: Cardinal Health is focused on improving its medical segment, which has been significantly impacted by inflation and global supply chain constraints. The company aims to achieve at least $650 million in segment profit by fiscal 2025 [4][10]. - **PPE Market Trends**: The company has experienced volatility in the Personal Protective Equipment (PPE) market, with pricing still elevated compared to pre-pandemic levels. The expectation is for prices to normalize as inventory levels stabilize [12][18][21]. - **Inflation Mitigation**: Cardinal Health is on track to mitigate $300 million of inflation impact in fiscal 2023, with expectations to reach a 50% mitigation rate by the end of the fiscal year [5][23][30]. Financial Performance - **Q1 Results**: The first quarter results were consistent with expectations, driven by a resilient demand environment. The company reported a 5% earnings growth in the prior year [3][7]. - **Shareholder Value**: Cardinal Health has committed to returning $1.5 billion to $2 billion to shareholders through share repurchases and dividends, with $1 billion already completed in Q1 [9][10]. Strategic Focus Areas - **Brand Portfolio Optimization**: The company is focused on optimizing and growing its Cardinal Health brand portfolio through new product innovation and capacity investments [6][7]. - **Pharmaceutical Segment Growth**: The pharmaceutical segment remains a priority, with investments in specialty areas and restructuring to enhance efficiency and decision-making [8][54]. - **Biosimilars Opportunity**: The company sees potential in the biosimilars market, particularly with the upcoming generic version of Humira, although significant contributions are expected to materialize in 2024 and beyond [60][64]. Operational Challenges - **Cost Pressures**: Labor costs and inflation remain elevated, impacting the company's margins. Cardinal Health is working to pass through these costs to customers while maintaining competitive pricing [42][51][44]. - **Inventory Management**: The company has faced challenges with high inventory costs and is working to normalize inventory levels while managing customer demand [12][15][19]. Governance and Future Outlook - **Board Enhancements**: Cardinal Health has added four new board members and established a Business Review Committee to support strategic reviews [10]. - **Future Focus**: The company anticipates continued focus on the medical improvement plan, capital deployment strategies, and the performance of its pharmaceutical segment in the upcoming fiscal year [76][78]. Additional Insights - **Customer Relationships**: Cardinal Health emphasizes the importance of strong relationships with customers across both medical and pharmaceutical segments, which can lead to synergies and cost efficiencies [66][68]. - **Investment in Technology**: The company plans to invest in automation and technology to enhance operational efficiency, particularly in distribution centers [72][73]. This summary encapsulates the key points discussed during the conference call, highlighting Cardinal Health's strategic priorities, financial performance, and operational challenges.